The Reported Human NADsyn2 Is Ammonia-dependent NAD Synthetase from a Pseudomonad*

Pawl Bieganowski‡ and Charles Brenner‡§
From the Structural Biology and Bioinformatics Program, Kimmel Cancer Center, Philadelphia, Pennsylvania 19107

Nicotinamide-adenine dinucleotide (NAD\(^+\)) synthetases catalyze the last step in NAD\(^+\) metabolism in the \textit{de novo}, import, and salvage pathways that originate from tryptophan (or aspartic acid), nicotinic acid, and nicotinamide, respectively, and converge on nicotinic acid mononucleotide. NAD\(^+\) synthetase converts nicotinic acid adenine dinucleotide to NAD\(^+\) via an adenylated intermediate. All of the known eukaryotic NAD\(^+\) synthetases are glutamine-dependent, hydrolyzing glutamine to glutamic acid to provide the attacking ammonia. In the prokaryotic world, some NAD\(^+\) synthetases are glutamine-dependent, whereas others can only use ammonia. Earlier, we noted a perfect correlation between presence of a domain related to nitrilase and glutamine dependence and then proved in the accompanying paper (Bieganowski, P., Pace, H. C., and Brenner, C. (2003) \textit{J. Biol. Chem.} 278, 33049–33055) that the nitrilase-related domain is an essential, obligate intramolecular, thiol-dependent glutamine amidotransferase in the yeast NAD\(^+\) synthetase, Qns1. Independently, human NAD\(^+\) synthetase was cloned and shown to depend on Cys-175 for glutamine-dependent but not ammonia-dependent NAD\(^+\) synthetase activity. Additionally, it was claimed that a 275 amino acid open reading frame putatively amplified from human glioma cell line LN229 encodes a human ammonia-dependent NAD\(^+\) synthetase and this was speculated largely to mediate NAD\(^+\) synthesis in human muscle tissues. Here we establish that the so-called NADsyn2 is simply ammonia-dependent NAD\(^+\) synthetase from \textit{Pseudomonas}, which is encoded on an operon with nicotinic acid phosphoribosyltransferase and, in some \textit{Pseudomonads}, with nicotinamidase.

NAD\(^+\) is essential as a co-enzyme for oxidation and reduction reactions and as a substrate for NAD\(^+\)-consuming enzymes such as the Sir2-related lysine deacetylases, the poly(ADP-ribose) polymerases, and the cyclic ADP-ribose synthetases (1, 2). Because the reaction catalyzed (amidation of nicotinic acid adenine dinucleotide) is the final common step in NAD\(^+\) biosynthesis from the \textit{de novo}, import, and salvage pathways, NAD\(^+\) synthetase is an essential enzyme in yeast (3). Eukaryotic NAD\(^+\) synthetase was first characterized 45 years ago in experiments establishing that a 275 amino acid open reading frame putatively amplified from human glioma cell line LN229 encodes a human ammonia-dependent NAD\(^+\) synthetase and this was speculated largely to mediate NAD\(^+\) synthesis in human muscle tissues. Here we establish that the so-called NADsyn2 is simply ammonia-dependent NAD\(^+\) synthetase from \textit{Pseudomonas}, which is encoded on an operon with nicotinic acid phosphoribosyltransferase and, in some \textit{Pseudomonads}, with nicotinamidase.

NAD\(^+\) is essential as a co-enzyme for oxidation and reduction reactions and as a substrate for NAD\(^+\)-consuming enzymes such as the Sir2-related lysine deacetylases, the poly(ADP-ribose) polymerases, and the cyclic ADP-ribose synthetases (1, 2). Because the reaction catalyzed (amidation of nicotinic acid adenine dinucleotide) is the final common step in NAD\(^+\) biosynthesis from the \textit{de novo}, import, and salvage pathways, NAD\(^+\) synthetase is an essential enzyme in yeast (3). Eukaryotic NAD\(^+\) synthetase was first characterized 45 years ago in experiments establishing that a 275 amino acid open reading frame putatively amplified from human glioma cell line LN229 encodes a human ammonia-dependent NAD\(^+\) synthetase and this was speculated largely to mediate NAD\(^+\) synthesis in human muscle tissues. Here we establish that the so-called NADsyn2 is simply ammonia-dependent NAD\(^+\) synthetase from \textit{Pseudomonas}, which is encoded on an operon with nicotinic acid phosphoribosyltransferase and, in some \textit{Pseudomonads}, with nicotinamidase.

EXPERIMENTAL PROCEDURES

Nucleic Acid and Protein Sequence Analyses—DNA sequence searches were performed with MEGA-BLAST (15) against all of the non-redundant data available at the National Center for Biotechnology Information and the Sanger Center. Protein sequence homologs were identified using BLASTP without position specific iteration (15). Neighboring genes were located in the ERGO database (16). Phylogenetic analysis of amino acid sequences was performed with PHYLIP (17).

* This work was supported by Research Grant CA77738 from the National Cancer Institute. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

‡ Present address: Depts. of Genetics and Biochemistry and the Norris Cotton Cancer Center, Dartmouth Medical School, HB7920, Lebanon, NH 03756.

§ To whom correspondence should be addressed. Tel.: 603-650-1912; Fax: 603-650-1188; E-mail: charles.brenner@dartmouth.edu.

1 The abbreviation used is: NAD\(^+\), nicotinamide-adenine dinucleotide.
RESULTS AND DISCUSSION

DNA Sequences from a Human Chromosome 22 CpG Library Do Not Consist Entirely of Chromosome 22 cDNAs—In their attempt to clone human NAD synthetase(s), Tsuchiya and co-workers (14) interrogated the public nucleic acid repositories with the sequence of *B. subtilis* NAD/H11545 synthetase (14). One of two sequences they identified as encoding an NAD/H11545 synthetase homolog (GenBank™ accession number HSA236685) had been deposited as a 1007-nucleotide sequence from a CpG island library prepared from flow-sorted human chromosome 22 (18). Ninety-nine clones from the chromosome 22 library had been sequenced. The authors reported that the majority represented known genes or sequences found among human expressed sequences (18). Additional clones represented chromosome 22 genomic DNA, human repetitive DNA, or Epstein-Barr viral DNA. These investigators were careful to point out that three clones from a similarly prepared chromosome 18 library matched *E. coli* sequences (18). Four clones including HSA236685 provided no match to any sequence, and no warrant was expressed about the "humanity" or expression of this deposition (18).

Conceptual translation of a 275 amino acid open reading frame from HSA236685 produces a polypeptide that is homologous to *B. subtilis* NAD/H11545 synthetase. Tsuchiya and co-workers (14) designed primers to amplify this sequence by reverse transcriptase-PCR from human glioma cell line LN229 and report cloning of a "human cDNA" that encodes a polypeptide with 271 of 275 identities to that encoded by HSA236685. The sequence was deposited in GenBank™ with accession number AB091317. Despite noting that there is no evidence for expression of this molecule from the extensive expressed sequence tag databases and with no Southern data or location of the gene in a human or other animal genomic assembly, the clone was termed "human NADsyn2 cDNA" and claimed to encode the first strictly ammonia-dependent NAD synthetase in eukaryotes (14). In fact, what was deposited has no feature diagnostic of a cDNA, such as an untranslated leader or sequences 3' of the stop codon terminating in poly(A). Surprised by the claim of a human ammonia-dependent NAD synthetase without a genomic clone for such a sequence from any eukaryote, we performed numerous searches through the publicly accessible databases. Because Tsuchiya and co-workers (14) did not identify a genomic DNA fragment encoding their "human NADsyn2," we examined the 1007-nucleotide sequence read of HSA236685 and found an 88% identical match (Fig. 1) over a common length of 975 nucleotides (864 of 975 nucleotides; p value $6.2 \times 10^{-170}$) with the partially assembled genome of *Pseudomonas fluorescens* SBW25 (www.sanger.ac.uk/Projects/P_fluorescens/). Thus, independent of coding potential, AB091317 appears to be of *Pseudomonal* origin.

Tsuchiya and co-workers (14) never published genomic or transcript sequences 5' to the initiator of "human NADsyn2." However, they did state that the NADsyn2 sequence contains an in-frame stop codon upstream of the initiator methionine in the same location as HSA236685 and encodes a polypeptide with 98.5% identity to that encoded by HSA236685 (14). As Tsuchiya and co-workers referred to the HSA236685 clone as a fragment of human genomic DNA, we examined the coding potential of the 136

---

**RESULTS AND DISCUSSION**

**DNA Sequences from a Human Chromosome 22 CpG Library Do Not Consist Entirely of Chromosome 22 cDNAs**—In their attempt to clone human NAD synthetase(s), Tsuchiya and co-workers (14) interrogated the public nucleic acid repositories with the sequence of *B. subtilis* NAD*-* synthetase (14). One of two sequences they identified as encoding an NAD*-* synthetase homolog (GenBank™ accession number HSA236685) had been deposited as a 1007-nucleotide sequence from a CpG island library prepared from flow-sorted human chromosome 22 (18). Ninety-nine clones from the chromosome 22 library had been sequenced. The authors reported that the majority represented known genes or sequences found among human expressed sequences (18). Additional clones represented chromosome 22 genomic DNA, human repetitive DNA, or Epstein-Barr viral DNA. These investigators were careful to point out that three clones from a similarly prepared chromosome 18 library matched *E. coli* sequences (18). Four clones including HSA236685 provided no match to any sequence, and no warrant was expressed about the “humanity” or expression of this deposition (18).

Conceptual translation of a 275 amino acid open reading frame from HSA236685 produces a polypeptide that is homologous to *B. subtilis* NAD*-* synthetase. Tsuchiya and co-workers (14) designed primers to amplify this sequence by reverse transcriptase-PCR from human glioma cell line LN229 and report cloning of a “human cDNA” that encodes a polypeptide with 271 of 275 identities to that encoded by HSA236685. The sequence was deposited in GenBank™ with accession number AB091317. Despite noting that there is no evidence for expression of this molecule from the extensive expressed sequence tag databases and with no Southern data or location of the gene in a human or other animal genomic assembly, the clone was termed “human NADsyn2 cDNA” and claimed to encode the first strictly ammonia-dependent NAD synthetase in eukaryotes (14). In fact, what was deposited has no feature diagnostic of a cDNA, such as an untranslated leader or sequences 3’ of the stop codon terminating in poly(A). Surprised by the claim of a human ammonia-dependent NAD synthetase without a genomic clone for such a sequence from any eukaryote, we performed numerous searches through the publicly accessible databases. Because Tsuchiya and co-workers (14) did not identify a genomic DNA fragment encoding their “human NADsyn2,” we examined the 1007-nucleotide sequence read of HSA236685 and found an 88% identical match (Fig. 1) over a common length of 975 nucleotides (864 of 975 nucleotides; p value $6.2 \times 10^{-170}$) with the partially assembled genome of *Pseudomonas fluorescens* SBW25 (www.sanger.ac.uk/Projects/P_fluorescens/). Thus, independent of coding potential, AB091317 appears to be of *Pseudomonal* origin.

**RESULTS AND DISCUSSION**

**DNA Sequences from a Human Chromosome 22 CpG Library Do Not Consist Entirely of Chromosome 22 cDNAs**—In their attempt to clone human NAD synthetase(s), Tsuchiya and co-workers (14) interrogated the public nucleic acid repositories with the sequence of *B. subtilis* NAD*-* synthetase (14). One of two sequences they identified as encoding an NAD*-* synthetase homolog (GenBank™ accession number HSA236685) had been deposited as a 1007-nucleotide sequence from a CpG island library prepared from flow-sorted human chromosome 22 (18). Ninety-nine clones from the chromosome 22 library had been sequenced. The authors reported that the majority represented known genes or sequences found among human expressed sequences (18). Additional clones represented chromosome 22 genomic DNA, human repetitive DNA, or Epstein-Barr viral DNA. These investigators were careful to point out that three clones from a similarly prepared chromosomal 18 library matched *E. coli* sequences (18). Four clones including HSA236685 provided no match to any sequence, and no warrant was expressed about the “humanity” or expression of this deposition (18).

Conceptual translation of a 275 amino acid open reading frame from HSA236685 produces a polypeptide that is homologous to *B. subtilis* NAD*-* synthetase. Tsuchiya and co-workers (14) designed primers to amplify this sequence by reverse transcriptase-PCR from human glioma cell line LN229 and report cloning of a “human cDNA” that encodes a polypeptide with 271 of 275 identities to that encoded by HSA236685. The sequence was deposited in GenBank™ with accession number AB091317. Despite noting that there is no evidence for expression of this molecule from the extensive expressed sequence tag databases and with no Southern data or location of the gene in a human or other animal genomic assembly, the clone was termed “human NADsyn2 cDNA” and claimed to encode the first strictly ammonia-dependent NAD synthetase in eukaryotes (14). In fact, what was deposited has no feature diagnostic of a cDNA, such as an untranslated leader or sequences 3’ of the stop codon terminating in poly(A). Surprised by the claim of a human ammonia-dependent NAD synthetase without a genomic clone for such a sequence from any eukaryote, we performed numerous searches through the publicly accessible databases. Because Tsuchiya and co-workers (14) did not identify a genomic DNA fragment encoding their “human NADsyn2,” we examined the 1007-nucleotide sequence read of HSA236685 and found an 88% identical match (Fig. 1) over a common length of 975 nucleotides (864 of 975 nucleotides; p value $6.2 \times 10^{-170}$) with the partially assembled genome of *Pseudomonas fluorescens* SBW25 (www.sanger.ac.uk/Projects/P_fluorescens/). Thus, independent of coding potential, AB091317 appears to be of *Pseudomonal* origin.
nucleotides of HSA236685 preceding the NAD\(^+\) synthetase initiator codon. Immediately \(5^\prime\) of the NAD\(^+\) synthetase initiator codon, we discovered an uninterrupted run of 43 amino acids followed by a TGA stop codon and one ATC codon. A BLASTP search (15) of nonredundant peptide data revealed that the 43 amino acid segment is the C terminus of nicotinic acid phosphoribosyltransferase (EC 2.4.2.11), the first enzyme in the Preiss-Handler pathway of NAD\(^+\) biosynthesis from nicotinic acid (NAD\(^+\) synthetase (EC 6.3.5.1) is the last) (4, 5). We then searched the ERGO database of completely and partially assembled genomes (16) to examine whether nicotinic acid phosphoribosyltransferase genes (bacterial orthologs usually termed \(\text{pncB}\)) have been found clustered with NAD\(^+\) synthetase genes (bacterial orthologs usually termed \(\text{nadE}\)). Indeed, as shown in Fig. 2, we found that \(\text{pncB}\) orthologs are the immediate upstream cistron with respect to \(\text{nadE}\) orthologs in \(\text{Enterococcus faecalis, Enterococcus faecium, Lactobacillus gasseri, Staphylococcus aureus, Staphylococcus epidermidis, Streptococcus equi, Streptococcus mutans, Streptococcus pneumoniae, and Streptococcus pyogenes.}\) Moreover, we found that a \(\text{pncA}\) ortholog encoding nicotinamidase (EC 3.5.1.19), which salvages nicotinamide to nicotinic acid for its subsequent use in the Preiss-Handler pathway, is located first in a three cistron operon in \(\text{Pseudomonas aeruginosa}\) (19). At the time of consulting the ERGO database, 513 complete and partial genomes were included, including 93 eukaryotic genomes (16). No eukaryotic NAD\(^+\) synthetase homolog was found without an N-terminal nitrilase-related domain, and no NAD\(^+\) synthetase gene was found in a eukaryote in an operon with genes for nicotinic acid phosphoribosyltransferase or nicotinamidase. Thus, the genomic organization of Tsuchiya’s NADsyn2 is bacterial and highly typical of a \(\text{Pseudomonad}\).

**FIG. 2.** \(\text{pncB}\) and \(\text{nadE}\) homologs, which are in an apparent operon in HSA236685, occur in the same organization exclusively in related bacterial genomes. Genome organization of \(\text{pncB}\) (nicotinic acid phosphoribosyltransferase), and \(\text{nadE}\) (ammonia-dependent NAD synthetase) cistrons in \(\text{E. faecalis, E. faecium, L. gasseri, P. aeruginosa, S. aureus, S. epidermidis, S. equi, S. mutans, S. pneumoniae, and S. pyogenes.}\) As with the sequence of HSA236685 and the fragment from \(\text{P. fluorescens SBW25, pncB and nadE sequences are arranged as consecutive cistrons in these genomes. In P. aeruginosa, pncA (nicotinamidase) is in the operon as well.}\)

**FIG. 3.** Phylogenetic analysis shows that HSA236685 and NADsyn2 \(\text{nadE}\) homologs are \(\text{Pseudomonal}\). The eight unique \(\text{nadE}\)-homologous sequences pulled out by BLASTP were aligned and submitted to phylogenetic analysis with PHYLIP. A nonrooted tree clearly locates HSA236685 and NADsyn2 as deriving from two strains of the same unidentified species of \(\text{Pseudomonas.}\) In this analysis, genus \(\text{Pseudomonas}\) was clearly separated from the other \(\gamma\)-proteobacteria. As other more distantly related \(\text{nadE}\) homologs were added to these alignments, it was
Possible to construct phylogenies that included more of the bacterial domain and, eventually, archaea and eukaryotes. Not surprisingly, vertebrate sequences were tightly grouped extremely far apart from the γ-proteobacteria (data not shown).

CONCLUSION

Tsukiyama and co-workers (14) amplified “human NADsyn2” from human cell lines using primers designed to amplify an ammonia-dependent NAD⁺ synthetase gene they spotted in GenBank™ deposited sequence HSA236685 (14). No data were presented, suggesting that the NADsyn2 clone required reverse transcriptase for amplification (14). The NADsyn2 clone is absent from all of the human expression databases (14) and genomic assemblies, whereas DNA sequence homologs with p values as low as $6.2 \times 10^{-170}$ are found in Pseudomonas and other bacterial genomic assemblies (this work). Pseudomonas species are well known laboratory contaminants capable of growing on disinfectants such as benzalkonium chloride as their sole carbon source (20). Northern blotting of murine tissues with a NADsyn2 probe showed extremely weak hybridization that was interpreted as specific signals in heart, skeletal muscle, and other tissues, whereas robust “expression” was seen in four human cell lines (14). Our interpretations are consistent with those of any eukaryotic NAD synthetase (3–5, 10). The simplest conclusion is that NADsyn2 is a typical Pseudomonas ammonia-dependent NAD synthetase.

Acknowledgment—We thank Andrei Osterman for helpful discussion and guidance with the ERGO database.

REFERENCES

1. Grozinger, C. M., and Schreiber, S. L. (2002) Chem. Biol. 9, 3–16
2. Ziegler, M. (2000) Eur. J. Biochem. 267, 1550–1564
3. Bieganskowski, P., Pace, H. C., and Brenner, C. (2003) J. Biol. Chem. 278, 33049–33055
4. Press, J., and Handler, P. (1958) J. Biol. Chem. 233, 488–492
5. Press, J., and Handler, P. (1958) J. Biol. Chem. 233, 493–500
6. Spencer, R. L., and Press, J. (1967) J. Biol. Chem. 242, 385–392
7. Rizzi, M., Nossi, C., Mattevi, A., Coda, A., Bolognesi, M., and Galizzi, A. (1996) EMBO J. 15, 5125–5134
8. Cantoni, R., Brunzoni, M., Labo, M., Rizzi, M., and Riccardi, G. (1998) J. Bacteriol. 180, 3218–3221
9. Zalkin, H., and Smith, J. L. (1998) Adv. Enzymol. Relat. Areas Mol. Biol. 72, 87–144
10. Pace, H. C., and Brenner, C. (2001) Genome Biol. 2, 0001.1–0001.9
11. Brenner, C. (2002) Curr. Opin. Struct. Biol. 12, 775–782
12. Pace, H. C., Hofmawadkekar, S. C., Draganescu, A., Huang, J., Biegansowski, P., Pekarsky, Y., Croce, C. M., and Brenner, C. (2000) Curr. Biol. 10, 967–977
13. Nakai, T., Hasegawa, T., Yamashita, E., Yamamoto, M., Kumasaka, T., Ueki, T., Nanba, H., Ikemura, T., Takahashi, S., Sato, M., and Tsukihara, T. (2000) Structure 8, 729–737
14. Hara, N., Yamada, T, Terasahima, M., Osagi, H., Shimoyama, M., and Tsukiya, M. (2003) J. Biol. Chem. 278, 10914–10921
15. Altschul, S. F., Madden, T. L., Schaffer, A. A., Zhang, J., Zhang, Z., Miller, W., and Lipman, D. J. (1997) Nucleic Acids Res. 25, 3389–3402
16. Overbeek, R., Larsen, N., Wilfus, T., D’Souza, M., Pusch, G., Selkov, E., Jr., Lisýlois, K., Joukov, V., Kazandzey, D., Anderson, I., Bhattacharyya, A., Burd, H., Gardner, W., Hanco, P., Kaplan, V., Mikhailova, N., Vaseva, O., Osterman, A., Vonstein, V., Fonstein, M., Ivanova, N., and Kyrpides, N. (2003) Nucleic Acids Res. 31, 164–171
17. Selenskiash, J. (1989) Cladistics 5, 164–166
18. Cross, S. H., Clark, V. H., Simmen, M. W., Bickmore, W. A., Maroon, H., Langford, C. F., Carter, N. P., and Bird, A. P. (2000) Mamm. Genome 11, 373–383
19. Stever, C. K., Pham, X. Q., Erwin, A. L., Mizoguchi, S. D., Warren, P., Hickey, M. J., Brinkman, F. S., Huhnaple, O. W., Kowalk, D. J., Lagrou, M., Garber, R. L., Goltry, L., Tontellino, E., Westbrock-Wadman, S., Yuan, Y., Brody, L. L., Coulter, S. N., Folger, K. R., Kas, A., Lethberg, K., Lim, R., Smith, K., Spencer, D., Wong, G. K., Wu, Z., Paulsen, I. T., Reizer, J., Saier, M. H., Hancock, R. E., Lory, S., and Olson, M. V. (2000) Nature 406, 959–964
20. Nagai, R., Ohta, S., Zenda, H., Matsumoto, H., and Makino, M. (1996) Biol. Pharm. Bull. 19, 873–875